Automated, miniaturized and accelerated drug discovery: AMADEUS
AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.
Projectdetails
Introduction
The mantra ‘Automation + Miniaturization = Acceleration’ is successfully applied in many research areas and technologies, but not in synthetic chemistry, which is largely believed to be not automatable. However, with the potential to accelerate discoveries while flattening costs, increase safety, streamline data generation, enhance reproducibility, and lower the environmental footprint, automation and miniaturization are two promising approaches to synthesis and are worthwhile to invest in.
Project Overview
I will engineer and validate a comprehensive technology platform, AMADEUS (Automated, MiniAturizeD, and acceleratEd drUg diScovery), which is able to synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence.
Technical Details
The AMADEUS process will be achieved by interfacing four different modules:
- A synthetic part based on acoustic droplet ejection technology.
- A UPLC MS QC and purification module.
- A flexible mounted screening unit.
- A machine learning module that retrieves and processes all relevant synthesis, QC, and screening ‘real-time’ data and automatically guides the iterative optimization cycle.
Applications
AMADEUS will be showcased with several medicinal chemistry, catalysis, and organic chemistry projects.
Challenge to Traditional Processes
With my project, I want to challenge the early drug discovery process, which for over 50 years in pharma companies around the world has (almost uniformly) been pursued and comprises two blocks:
- A high throughput screen relying on millions of curated and stored compounds.
- The subsequent hit-to-lead optimization phase often called the ‘design, make, test cycle’.
Impact
AMADEUS will contribute to the accelerated discovery of drugs for unmet medical needs and ultimately reduce drug costs for patients.
Sustainability
AMADEUS is a highly sustainable synthesis platform.
Democratization of Drug Discovery
AMADEUS will help democratize drug discovery.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 3.409.401 |
Totale projectbegroting | € 3.409.401 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERZITA PALACKEHO V OLOMOUCIpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
High-throughput combinatory drugs testing on in vitro 3D cells model platformThe project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer. | ERC Proof of... | € 150.000 | 2023 | Details |
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistanceAI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance. | ERC Synergy ... | € 10.968.734 | 2025 | Details |
Scalable Microbial Metabolite Discovery Through Synthetic BiologyThis project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development. | ERC Starting... | € 1.490.250 | 2024 | Details |
High throughput development platform for oligonucleotide aptamersSPARXS is an innovative platform that enables rapid design of affinity probes by simultaneously analyzing binding kinetics and sequences of millions of aptamers for diverse applications. | ERC Proof of... | € 150.000 | 2024 | Details |
dAta-dRiven integrated approaches to CHemIcal safety assessMEnt and Drug dEvelopmentThe ARCHIMEDES project aims to revolutionize chemical and drug development by integrating toxicogenomics, AI, and a Knowledge Graph to enhance safety and innovation in a regulatory-compliant manner. | ERC Consolid... | € 2.000.000 | 2022 | Details |
High-throughput combinatory drugs testing on in vitro 3D cells model platform
The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance
AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.
Scalable Microbial Metabolite Discovery Through Synthetic Biology
This project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development.
High throughput development platform for oligonucleotide aptamers
SPARXS is an innovative platform that enables rapid design of affinity probes by simultaneously analyzing binding kinetics and sequences of millions of aptamers for diverse applications.
dAta-dRiven integrated approaches to CHemIcal safety assessMEnt and Drug dEvelopment
The ARCHIMEDES project aims to revolutionize chemical and drug development by integrating toxicogenomics, AI, and a Knowledge Graph to enhance safety and innovation in a regulatory-compliant manner.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Next generation HPC/QC in silico drug discovery platform for de novo designATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Drug Discovery IntelligenceHet project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties. | Mkb-innovati... | € 20.000 | 2020 | Details |
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
Accelerated Discovery Nanobody PlatformThe ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing. | EIC Pathfinder | € 3.315.441 | 2024 | Details |
Accelerating the discovery of high-performance electrocatalysts through artificial intelligence and robotics technologyDunia is transforming electrocatalyst discovery using AI and robotics to accelerate the process by 90% and reduce costs by 60-70%, enabling carbon-neutral production from captured CO2. | EIC Accelerator | € 2.499.525 | 2024 | Details |
Next generation HPC/QC in silico drug discovery platform for de novo design
ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.
Drug Discovery Intelligence
Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.
Accelerated Discovery Nanobody Platform
The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.
Accelerating the discovery of high-performance electrocatalysts through artificial intelligence and robotics technology
Dunia is transforming electrocatalyst discovery using AI and robotics to accelerate the process by 90% and reduce costs by 60-70%, enabling carbon-neutral production from captured CO2.